Reviewing Supreme Cannabis (OTCMKTS:SPRWF) and Talphera (NASDAQ:TLPH)

Talphera (NASDAQ:TLPH) and Supreme Cannabis (OTCMKTS:SPRWF) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, profitability, risk and institutional ownership.

Profitability

This table compares Talphera and Supreme Cannabis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Talphera	N/A	-87.28%	-51.36%
Supreme Cannabis	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Talphera and Supreme Cannabis, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Talphera	1	1	2	0	2.25
Supreme Cannabis	0	0	0	0	0.00

Talphera currently has a consensus target price of $3.00, indicating a potential upside of 150.00%. Given Talphera’s stronger consensus rating and higher probable upside, equities analysts plainly believe Talphera is more favorable than Supreme Cannabis.

Insider and Institutional Ownership

37.7% of Talphera shares are held by institutional investors. 3.5% of Talphera shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Talphera and Supreme Cannabis”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Talphera	$30,000.00	2,076.40	-$14.29 million	($0.27)	-4.44
Supreme Cannabis	N/A	N/A	N/A	N/A	N/A

Supreme Cannabis has lower revenue, but higher earnings than Talphera.

Summary

Talphera beats Supreme Cannabis on 6 of the 8 factors compared between the two stocks.

About Talphera

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

About Supreme Cannabis

The Supreme Cannabis Company, Inc. engages in the production of medical cannabis products in Canada. The company was formerly known as Supreme Pharmaceuticals Inc. and changed its name to The Supreme Cannabis Company, Inc. in December 2017. The Supreme Cannabis Company, Inc. was incorporated in 1979 and is headquartered in Toronto, Canada.